Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF FINANCIAL OFFICER | September 01, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date September 01, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 20,854 |
Ending reported balance
After 2026-09-01 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-01 · Exercise / conversion · Acquired 2,694 · Balance 18,848 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 2 · 2026-09-01 · Exercise / conversion · Acquired 1,750 · Balance 20,598 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 1,591 · Balance 22,189 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 3,069 · Balance 25,258 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Tax withholding · Disposed 4,404 · Balance 20,854 |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,800 |
Reported balance
After 2026-09-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-01 · Grant · Acquired 7,800 · Balance 7,800 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 9,206 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Exercise / conversion · Disposed 3,069 · Balance 9,206 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,182 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Exercise / conversion · Disposed 1,591 · Balance 3,182 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,750 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 1,750 · Balance 1,750 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,694 · Balance 0 F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 31,150 |
Reported balance
After 2026-09-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-01 · Grant · Acquired 31,150 · Balance 31,150 F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F2: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026.
F3: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F5: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,592 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010004 · form4-04032025_090414.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,724 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 21:04 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-010004 · form4-04032025_090414.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 15,944 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001415889-25-008846 · form4-03242025_080343.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,374 Underlying: Class A Ordinary Share · 15,944 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 15,944 | $23.11 | $368,465.84 |
DisclosureSEC source: 0001415889-25-008846 · form4-03242025_080343.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,382 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $23.10 and $23.185. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 15,944 | $12.97 | $206,793.68 |
DisclosureSEC source: 0001415889-25-008846 · form4-03242025_080343.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| March 19, 2025 Filed Mar 19, 2025 21:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 8,879 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001415889-25-008622 · form4-03192025_090329.xml · derivative · entry 9 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,318 Underlying: Class A Ordinary Share · 8,879 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021. Read SEC document |
| March 19, 2025 Filed Mar 19, 2025 21:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 8,879 | $23.10 | $205,104.90 |
DisclosureSEC source: 0001415889-25-008622 · form4-03192025_090329.xml · nonDerivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,382 F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| March 19, 2025 Filed Mar 19, 2025 21:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 8,879 | $12.97 | $115,160.63 |
DisclosureSEC source: 0001415889-25-008622 · form4-03192025_090329.xml · nonDerivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,261 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 11,464 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001415889-25-008622 · form4-03192025_090329.xml · derivative · entry 8 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,197 Underlying: Class A Ordinary Share · 11,464 shares Expires 2031-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 11,464 | $23.10 | $264,818.40 |
DisclosureSEC source: 0001415889-25-008622 · form4-03192025_090329.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,382 F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $23.10 and $23.13. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 21:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 11,464 | $12.97 | $148,688.08 |
DisclosureSEC source: 0001415889-25-008622 · form4-03192025_090329.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 872 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008622 · form4-03192025_090329.xml · derivative · entry 7 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Share · 872 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 448 | $22.61 | $10,129.28 |
DisclosureSEC source: 0001415889-25-008622 · form4-03192025_090329.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,382 Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:53 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-008622 · form4-03192025_090329.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 36,372 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001415889-25-008115 · form4-03142025_080318.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,288 Underlying: Class A Ordinary Share · 36,372 shares Expires 2032-08-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 36,372 | $22.25 | $809,277.00 |
DisclosureSEC source: 0001415889-25-008115 · form4-03142025_080318.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,958 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $22.25 and $22.27. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 20:37 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 36,372 | $11.97 | $435,372.84 |
DisclosureSEC source: 0001415889-25-008115 · form4-03142025_080318.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 18,860 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-24-028844 · form4-12102024_091222.xml · derivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,552 Underlying: Class A Ordinary Share · 18,860 shares Expires 2032-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 8, 2022. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 18,860 | $21.38 | $403,226.80 |
DisclosureSEC source: 0001415889-24-028844 · form4-12102024_091222.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,958 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.755. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 18,860 | $11.10 | $209,346.00 |
DisclosureSEC source: 0001415889-24-028844 · form4-12102024_091222.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,818 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 2,406 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001415889-24-028844 · form4-12102024_091222.xml · derivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,528 Underlying: Class A Ordinary Share · 2,406 shares Expires 2033-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 8,969 | $21.27 | $190,770.63 |
DisclosureSEC source: 0001415889-24-028844 · form4-12102024_091222.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,958 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.31. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 2,406 | $10.76 | $25,888.56 |
DisclosureSEC source: 0001415889-24-028844 · form4-12102024_091222.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 00:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 1,123 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001415889-24-028431 · form4-12062024_121225.xml · derivative · entry 9 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,934 Underlying: Class A Ordinary Shares · 1,123 shares Expires 2033-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 00:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 1,123 | $21.25 | $23,863.75 |
DisclosureSEC source: 0001415889-24-028431 · form4-12062024_121225.xml · nonDerivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,958 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.265. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 00:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,123 | $10.76 | $12,083.48 |
DisclosureSEC source: 0001415889-24-028431 · form4-12062024_121225.xml · nonDerivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 00:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 5,024 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001415889-24-028431 · form4-12062024_121225.xml · derivative · entry 8 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,057 Underlying: Class A Ordinary Share · 5,024 shares Expires 2033-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 00:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 5,024 | $21.25 | $106,760.00 |
DisclosureSEC source: 0001415889-24-028431 · form4-12062024_121225.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,958 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.25 and $21.265. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 00:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 5,024 | $10.76 | $54,058.24 |
DisclosureSEC source: 0001415889-24-028431 · form4-12062024_121225.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| December 03, 2024 Filed Dec 6, 2024 00:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 8,969 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001415889-24-028431 · form4-12062024_121225.xml · derivative · entry 7 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,081 Underlying: Class A Ordinary Share · 8,969 shares Expires 2033-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F5 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 2, 2023. Read SEC document |
| December 03, 2024 Filed Dec 6, 2024 00:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 8,969 | $21.45 | $192,385.05 |
DisclosureSEC source: 0001415889-24-028431 · form4-12062024_121225.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,958 F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $21.26 and $21.70. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| December 03, 2024 Filed Dec 6, 2024 00:14 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 8,969 | $10.76 | $96,506.44 |
DisclosureSEC source: 0001415889-24-028431 · form4-12062024_121225.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022859 · form4-09052024_120941.xml · derivative · entry 9 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,861 Underlying: Class A Ordinary Share · 1,861 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 956 | $26.74 | $25,563.44 |
DisclosureSEC source: 0001415889-24-022859 · form4-09052024_120941.xml · nonDerivative · entry 4 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,958 Read SEC document |
| September 02, 2024 Filed Sep 5, 2024 00:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 1,861 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022859 · form4-09052024_120941.xml · nonDerivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,914 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 1,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022859 · form4-09052024_120941.xml · derivative · entry 8 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,250 Underlying: Class A Ordinary Share · 1,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. F5 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022859 · form4-09052024_120941.xml · derivative · entry 7 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,388 Underlying: Class A Ordinary Share · 2,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 33,150 | $0.00 Strike: $26.74 | $0.00 |
DisclosureSEC source: 0001415889-24-022859 · form4-09052024_120941.xml · derivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,150 Underlying: Class A Ordinary Share · 33,150 shares Expires 2034-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 6,365 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-022859 · form4-09052024_120941.xml · derivative · entry 5 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,365 Underlying: Class A Ordinary Share · 6,365 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024. Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Ordinary Share | 2,260 | $26.74 | $60,432.40 |
DisclosureSEC source: 0001415889-24-022859 · form4-09052024_120941.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,053 Read SEC document |
| September 01, 2024 Filed Sep 5, 2024 00:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 4,444 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-022859 · form4-09052024_120941.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,313 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionShare Option · Derivative | 24,248 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-24-020106 · form4-07252024_080736.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,412 Underlying: Class A Ordinary Share · 24,248 shares Expires 2032-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023. F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | SaleClass A Ordinary Share | 24,248 | $24.79 | $601,107.92 |
DisclosureSEC source: 0001415889-24-020106 · form4-07252024_080736.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,253 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging between $24.72 and $25.095. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. Read SEC document |
| July 23, 2024 Filed Jul 25, 2024 20:32 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Ordinary Share | 24,248 | $11.10 | $269,152.80 |
DisclosureSEC source: 0001415889-24-020106 · form4-07252024_080736.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 991 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-011764 · form4-04302024_080421.xml · derivative · entry 3 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 990 Underlying: Class A Common Share · 991 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021. F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 509 | $17.88 | $9,100.92 |
DisclosureSEC source: 0001415889-24-011764 · form4-04302024_080421.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,253 Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 20:35 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 991 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-011764 · form4-04302024_080421.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,762 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,694 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010509 · form4-04082024_090417.xml · derivative · entry 6 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,921 Underlying: Class A Common Share · 2,694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 791 | $17.90 | $14,158.90 |
DisclosureSEC source: 0001415889-24-010509 · form4-04082024_090417.xml · nonDerivative · entry 2 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,771 Read SEC document |
| April 08, 2024 Filed Apr 8, 2024 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,694 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010509 · form4-04082024_090417.xml · nonDerivative · entry 1 Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.